- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Biosante Pharmaceuticals Inc
Add to PortfolioBPAX:US
0.5183 USD 0.0013 0.25%As of 20:10:00 ET on 05/25/2012.
Snapshot for Biosante Pharmaceuticals Inc (BPAX)
| Open: | 0.5196 | Day's Range: | 0.5025 - 0.5400 | Volume: | 1,658,523 | Bid: | 0.5199 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 0.5196 | 52wk Range: | 0.3394 - 4.0200 | 1-Yr Rtn: | -82.19% | Ask: | 0.5200 |
Key Statistics for BPAX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.4500 |
| Est. EPS (USD) (12/2012) | -0.2200 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 62.62 |
| Shares Outstanding (M) | 120.83 |
| Enterprise Value (M USD) (ttm) | 23.64 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 1.6535 |
| Price/Sale (ttm) | 111.9694 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/25/2012 |
More BPAX Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for BPAX
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for BPAX
BioSante Pharmaceuticals, Inc. is an emerging pharmaceutical company. The Company develops hormone replacement products to treat testosterone deficiency in men and estrogen deficiency in women. BioSante is also developing its nanoparticulate based platform technology for novel vaccines, vaccine adjuvant and drug delivery systems.
| Louis W SullivanChairman | Stephen M SimesVice Chairman/President/CEO |
| Phillip B DonenbergSenior VP:Finance/CFO/Secy | Michael C SnabesSenior VP:Medical Affairs |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page